Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2022-09-30 AGM Information
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司2022年第一次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as materials for the "2022 First Extraordinary General Meeting" of Changchun Baike Biotechnology Co., Ltd. It contains detailed meeting instructions, agenda, and multiple proposals related to the company's equity incentive management measures and restricted stock incentive plans. The content is typical of materials prepared and distributed for a shareholders' meeting to inform and guide shareholders on the meeting's proceedings and proposals to be voted on. There is no indication that this is a report of voting results, nor is it a transcript or a financial report. It is not a proxy solicitation or remuneration report. The document is clearly the meeting materials for a shareholders' meeting, specifically an Extraordinary General Meeting (EGM). According to the filing definitions, presentations and materials shared during the Annual General Meeting (AGM) or Extraordinary General Meeting fall under "AGM Information" (AGM-R). Therefore, the appropriate classification is AGM-R with high confidence.
2022-09-30 Chinese
长春百克生物科技股份公司监事会关于公司2022年限制性股票激励计划（草案）的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from the supervisory board regarding the company's 2022 restricted stock incentive plan draft. It references relevant laws and regulations about stock incentive plans and confirms the legality and compliance of the plan. The document does not contain financial statements or results but is an official opinion on a stock incentive plan draft. This type of document fits best under Regulatory Filings (RNS) as it is a compliance and regulatory disclosure related to corporate governance and incentive plans, not a full report or announcement of voting results or remuneration details.
2022-09-23 Chinese
长春百克生物科技股份公司第五届董事会独立董事关于第五届董事会第九次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion from the independent directors of Changchun Baike Biotechnology Co., Ltd. regarding matters discussed at the ninth meeting of the fifth board of directors. It includes opinions on a 2022 restricted stock incentive plan, its assessment management methods, and the appointment of a board secretary. The document references compliance with company law, securities law, and stock exchange listing rules, and it is signed by independent directors. The content is focused on governance and board-related decisions rather than financial results or audit information. The document length is 2430 characters, which is relatively short and does not contain financial statements or detailed financial data. It is not a report of financial results, audit, or regulatory filing but rather a formal board/management announcement related to governance and management decisions. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-09-23 Chinese
长春百克生物科技股份公司关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice about convening the 2022 first extraordinary general meeting of shareholders for Changchun Baike Biotechnology Co., Ltd. It details the meeting date, voting methods, agenda items, and instructions for shareholders to attend and vote. It does not contain financial statements or results but is an announcement related to a shareholders meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), as it provides information to shareholders to solicit votes for the meeting.
2022-09-23 Chinese
长春百克生物科技股份公司股权激励管理办法
Governance Information Classification · 95% confidence The document is titled as a "股权激励管理办法" which translates to "Equity Incentive Management Measures". It is a detailed policy document outlining the rules, procedures, and regulations for the company's equity incentive plan, including eligibility, types of equity incentives (restricted stock, stock options), implementation procedures, disclosure requirements, and supervisory management. It is a regulatory or governance-related internal policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements or earnings data, nor is it a meeting presentation or voting result. It is a governance-related document detailing internal rules and practices regarding equity incentives for directors, management, and employees. Therefore, the most appropriate classification is Governance Information (CGR). The document length and detail confirm it is not a brief announcement or a report publication announcement.
2022-09-23 Chinese
长春百克生物科技股份公司2022年限制性股票激励计划首次授予激励对象名单
Share Issue/Capital Change Classification · 95% confidence The document is a list of recipients for a restricted stock incentive plan, detailing the allocation of restricted shares to senior management and key personnel. It includes specific numbers of shares granted and percentages relative to total shares. This type of document is related to share-based compensation and capital changes rather than a full financial report or announcement of voting results. It is not an annual report, earnings release, or management report. It is also not a regulatory filing or announcement of a report publication. The content fits best under Share Issue/Capital Change (SHA) as it concerns the issuance of restricted stock as part of an incentive plan.
2022-09-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.